Eli Lilly (LLY) Reports Positive Phase 1b Verve-102 Study Results

Eli Lilly and Company (NYSE:LLY) is one of the 12 Most Profitable Stocks to Invest In.

On May 25, 2026, Eli Lilly and Company (NYSE:LLY) announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein cholesterol after a single infusion. In an interim analysis of 35 participants, one dose of Verve-102 produced dose-dependent mean PCSK9 reductions ranging from 51% to 88%, from the 0.3 mg/kg dose to the 1.0 mg/kg dose. Corresponding mean LDL-C reductions were 9%, 44%, 45%, 33%, 51%, and 62%, with durability observed for up to 18 months after treatment.

Eli Lilly (LLY) Reports Positive Phase 1b Verve-102 Study Results

On May 21, 2026, Wolfe Research said Eli Lilly and Company (NYSE:LLY) reported pivotal Phase 3 results for retatrutide showing “class-leading” weight loss of up to 26.1% at 80 weeks and over 30% at 104 weeks in higher-BMI participants. Wolfe said the data also showed broad improvements in key cardiometabolic risk markers, further strengthening Eli Lilly’s GLP-1 franchise leadership and obesity therapeutics profile. Wolfe maintained an Outperform rating and a $1,350 price target on the shares.

Meanwhile, RBC Capital maintained an Outperform rating and a $1,250 price target on Eli Lilly and Company (NYSE:LLY). RBC said the retatrutide Phase 3 trial was a clean win, citing a clean safety profile and best-in-class efficacy across all doses. RBC said it is modeling a retatrutide launch in 2027, 2030 sales of $4.9B, and 2034 sales of $11.0B with a 70% probability of success.

Eli Lilly and Company (NYSE:LLY) discovers, develops, manufactures, and markets human pharmaceutical products internationally.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1